GRAL
GRAL
NASDAQ · Biotechnology

Grail Inc

$107.97
+27.20 (+33.68%)
As of Sep 21, 9:57 PM ET ·
Analyst Consensus
Buy
15
Analysts
High
Coverage
Buy 9 60%
Hold 6 40%
Sell 0 0%
Price Target
Analyst Price Target -68.9% upside
Low Target $28.45
Average Target $33.59
High Target $56.21
Current Price $107.97
Current
$107.97
Target
$33.59
$28.45 $33.59 avg $56.21
Scenario Analysis
Bear Case
$28.45
-73.7%
Low target
Base Case
$33.59
-68.9%
Avg target
Bull Case
$56.21
+-47.9%
High target
Risk/Reward
0.7x
Unfavorable
Price in Context
52-Week High
$118.84
-9.1% from high
52-Week Low
$36.98
+192.0% from low
50-Day SMA
$97.75
+10.5% vs SMA
200-Day SMA
$64.49
+67.4% vs SMA
RSI (14)
50.6
Neutral
Target vs 52W High
$33.59
-71.7% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 39 82% $257.58 -2.6%
AMGN
Amgen Inc
Hold 43 47% $190.87 -51.5%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +140.9%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 36 81% $438.34 -14.2%
REGN
Regeneron Pharmaceuticals
Buy 38 68% $76.80 -90.4%
MRNA
Moderna Inc
Hold 30 37% $149.45 -13.6%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -61.4%
RVMD
Revolution Medicines Inc
Strong Buy 28 93% $114.11 -40.8%